Sage Therapeutics Expects Cash & Equivalents Plus Funding To Support Its Operations Into 2026; Expects ZULRESSO Revenues To Continue To Decrease Over Time
Author: Benzinga Newsdesk | April 25, 2024 06:40am
The Company does not anticipate receipt of any additional milestone payments from collaborations in the remainder of 2024. The Company anticipates operating expenses will decrease in 2024 relative to 2023. With the availability of ZURZUVAE in the U.S. as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.
Posted In: SAGE
